临床试验 以下为当前的临床试验。26 研究 皮肤科 (仅限仍在招募的研究). 按院区、状态和其他条件筛选该研究列表。 A Study to Evaluate the Effectiveness and Safety of PCS499 in Treating Ulcerations in Patients who have Necrobiosis Lipoidica Scottsdale/Phoenix, Ariz., Rochester, Minn. The purpose of this study is to evaluate the effectiveness of PCS499 at 6 Months in treating ulcerations in patients who have necrobiosis lipoidica. C. Albicans during Early Life Predisposes Individuals to Atopy Rochester, Minn. The purpose of this study is to evaluate the contribution of C. albicans to dysbiotic microbial communities of mucosal tissues in pediatric populations. Prospective sampling across multiples tissue sites in a pediatric cohort will be used to assess which tissues are colonized by C. albicans and associated with microbial dysbiosis seen in atopic dermitis. We hypothesize presence of C. albicans in the microbial communities in early life is associated with atopy. We will assess the presence of C. albicans in the microbial communities of a population of children at-risk for atopic dermatitis compared to healthy controls who do not have an underlying risk for atopy based off family history. In tandem with the collection of human samples, we will utilize mouse models to validate the influence of C. albicans exposure during early life on the systemic immune populations. A Study to Define Axl Expression Level in Skin Biopsy Specimens from Patients with Skin Cancer in Relation to Chronic Lymphocytic Leukemia Rochester, Minn. The purpose of this study is to define the presence and role of Axl in the risk of skin cancers in patients with CLL as well as non-CLL patients. A Study to Evaluate Dupilumab as a Treatment for Moderate-to-Severe, Chronic Hepatic Pruritus Jacksonville, Fla. The purpose of this study is to investigate the potential effectiveness of dupilumab in the treatment of moderate-to-severe, chronic hepatic pruritus. An Expansion Study to Evaluate Dose Escalation, Safety and Tolerability of SAR444881 in Patients with Advanced Solid Tumors Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of SAR444881 alone and in combination with pembrolizumab or with cetuximab. The study will enroll advanced cancer patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy and will be comprised of two parts - an initial "3 + 3" dose escalation phase (Part 1) with Sub-Parts 1A (monotherapy SAR444881), 1B (SAR444881 in combination with pembrolizumab) and 1C (SAR444881 in combination with cetuximab) followed by a dose optimization/expansion phase (Part 2), including Sub-Part 2A (Dose Optimization) with Cohorts A1 (SAR444881 in combination with pembrolizumab, carboplatin, and pemetrexed), A2 (SAR444881 in combination with pembrolizumab), B1 (SAR444881 in combination with pembrolizumab and later therapy), and C1 (SAR444881 in combination with cetuximab and later therapy), as well as Sub-Part 2B (Dose Expansion) with Cohort D1 (monotherapy SAR444881). A Study to Evaluate Perceptions of Midline Sternotomy Scar in Children and Young Adults Rochester, Minn. The purpose of this study is to evaluate how children and young adults perceive their midline sternotomy scars (in terms of appearance, associated symptoms, consciousness, satisfaction with appearance/symptoms, and impact on quality of life)? A Study of DNA Markers for the Detection of Metastatic Melanoma in Blood Rochester, Minn. The purpose of this study is to discover and validate DNA methylation-based markers that identify patients with metastatic melanoma based on the detection of such markers in patient blood with the ultimate goal of using blood-based multi-marker testing as a method of disease surveillance in melanoma patients. A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection Jacksonville, Fla. The purpose of this study is to compare the drug levels of nivolumab administered subcutaneously versus intravenous administration in participants with melanoma following complete resection. Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Scottsdale/Phoenix, Ariz. The purpose of this study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and radiation therapy (RT). The secondary objectives of the study is to compare the overall survival (OS) of high-risk CSCC patients treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and RT -To compare the effect of adjuvant cemiplimab with that of placebo on patients' freedom from locoregional recurrence (FFLRR) after surgery and RT; to compare the effect of adjuvant cemiplimab with that of placebo on patients' freedom from distant recurrence (FFDR) after surgery and RT; to compare the effect of adjuvant cemiplimab with that of placebo on the cumulative incidence of second primary CSCC tumors (SPTs) after surgery and RT; to evaluate the safety of adjuvant cemiplimab and that of placebo in high-risk CSCC patients after surgery and RT; to assess cemiplimab pharmacokinetics and immunogenicity in human serum. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the feasibility of molecular characterization based on tumor mutational burden (TMB) for participant stratification, as assessed by the proportion of participants with less than or equal to a 21-day turnaround time for biopsy results in Stage I of the study. Also, to evaluate the feasibility of molecular characterization based on TMB and gene expression profiling (GEP) (for TIS - tumor inflammation signature) for stratification in the overall study (Stage I and Stage II). Additinoally, to evaluate the effectiveness by overall response rate (ORR – defined as confirmed and unconfirmed partial responses plus complete responses) of cabozantinib plus nivolumab in each disease cohort, both across and within tumor biomarker subgroups. Pagination 临床研究 PrevPrevious Page Go to page 11 Go to page 22 Go to page 33 NextNext Page 以下为当前的临床试验。26 研究 皮肤科 (仅限仍在招募的研究). 按院区、状态和其他条件筛选该研究列表。 A Study to Evaluate the Effectiveness and Safety of PCS499 in Treating Ulcerations in Patients who have Necrobiosis Lipoidica Scottsdale/Phoenix, Ariz., Rochester, Minn. The purpose of this study is to evaluate the effectiveness of PCS499 at 6 Months in treating ulcerations in patients who have necrobiosis lipoidica. C. Albicans during Early Life Predisposes Individuals to Atopy Rochester, Minn. The purpose of this study is to evaluate the contribution of C. albicans to dysbiotic microbial communities of mucosal tissues in pediatric populations. Prospective sampling across multiples tissue sites in a pediatric cohort will be used to assess which tissues are colonized by C. albicans and associated with microbial dysbiosis seen in atopic dermitis. We hypothesize presence of C. albicans in the microbial communities in early life is associated with atopy. We will assess the presence of C. albicans in the microbial communities of a population of children at-risk for atopic dermatitis compared to healthy controls who do not have an underlying risk for atopy based off family history. In tandem with the collection of human samples, we will utilize mouse models to validate the influence of C. albicans exposure during early life on the systemic immune populations. A Study to Define Axl Expression Level in Skin Biopsy Specimens from Patients with Skin Cancer in Relation to Chronic Lymphocytic Leukemia Rochester, Minn. The purpose of this study is to define the presence and role of Axl in the risk of skin cancers in patients with CLL as well as non-CLL patients. A Study to Evaluate Dupilumab as a Treatment for Moderate-to-Severe, Chronic Hepatic Pruritus Jacksonville, Fla. The purpose of this study is to investigate the potential effectiveness of dupilumab in the treatment of moderate-to-severe, chronic hepatic pruritus. An Expansion Study to Evaluate Dose Escalation, Safety and Tolerability of SAR444881 in Patients with Advanced Solid Tumors Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of SAR444881 alone and in combination with pembrolizumab or with cetuximab. The study will enroll advanced cancer patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy and will be comprised of two parts - an initial "3 + 3" dose escalation phase (Part 1) with Sub-Parts 1A (monotherapy SAR444881), 1B (SAR444881 in combination with pembrolizumab) and 1C (SAR444881 in combination with cetuximab) followed by a dose optimization/expansion phase (Part 2), including Sub-Part 2A (Dose Optimization) with Cohorts A1 (SAR444881 in combination with pembrolizumab, carboplatin, and pemetrexed), A2 (SAR444881 in combination with pembrolizumab), B1 (SAR444881 in combination with pembrolizumab and later therapy), and C1 (SAR444881 in combination with cetuximab and later therapy), as well as Sub-Part 2B (Dose Expansion) with Cohort D1 (monotherapy SAR444881). A Study to Evaluate Perceptions of Midline Sternotomy Scar in Children and Young Adults Rochester, Minn. The purpose of this study is to evaluate how children and young adults perceive their midline sternotomy scars (in terms of appearance, associated symptoms, consciousness, satisfaction with appearance/symptoms, and impact on quality of life)? A Study of DNA Markers for the Detection of Metastatic Melanoma in Blood Rochester, Minn. The purpose of this study is to discover and validate DNA methylation-based markers that identify patients with metastatic melanoma based on the detection of such markers in patient blood with the ultimate goal of using blood-based multi-marker testing as a method of disease surveillance in melanoma patients. A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection Jacksonville, Fla. The purpose of this study is to compare the drug levels of nivolumab administered subcutaneously versus intravenous administration in participants with melanoma following complete resection. Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Scottsdale/Phoenix, Ariz. The purpose of this study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and radiation therapy (RT). The secondary objectives of the study is to compare the overall survival (OS) of high-risk CSCC patients treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and RT -To compare the effect of adjuvant cemiplimab with that of placebo on patients' freedom from locoregional recurrence (FFLRR) after surgery and RT; to compare the effect of adjuvant cemiplimab with that of placebo on patients' freedom from distant recurrence (FFDR) after surgery and RT; to compare the effect of adjuvant cemiplimab with that of placebo on the cumulative incidence of second primary CSCC tumors (SPTs) after surgery and RT; to evaluate the safety of adjuvant cemiplimab and that of placebo in high-risk CSCC patients after surgery and RT; to assess cemiplimab pharmacokinetics and immunogenicity in human serum. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the feasibility of molecular characterization based on tumor mutational burden (TMB) for participant stratification, as assessed by the proportion of participants with less than or equal to a 21-day turnaround time for biopsy results in Stage I of the study. Also, to evaluate the feasibility of molecular characterization based on TMB and gene expression profiling (GEP) (for TIS - tumor inflammation signature) for stratification in the overall study (Stage I and Stage II). Additinoally, to evaluate the effectiveness by overall response rate (ORR – defined as confirmed and unconfirmed partial responses plus complete responses) of cabozantinib plus nivolumab in each disease cohort, both across and within tumor biomarker subgroups. Pagination 临床研究 PrevPrevious Page Go to page 11 Go to page 22 Go to page 33 NextNext Page 申请预约 专业团队研究 June 21, 2024 Share on: FacebookTwitterWeChatWeChatCloseWeibo 皮肤科部分申请预约概述测试与程序主治医生专业团队临床试验研究患者故事费用与保险Mayo Clinic 新闻转诊 研究完全以患者为中心。 请参见副本 供视频使用 研究完全以患者为中心。 [音乐播放] 妙佑医疗国际神经学教授 Joseph Sirven 医学博士:妙佑医疗的使命以患者为中心。患者第一。我们的使命和研究是为了更好地帮助患者,提供以患者为中心的护理。在很多方面,这是一个循环。这个过程可能很简单,就是先在实验室里出现一个想法,然后带到病床旁加以实施,如果一切顺利,对患者有所助益, 就形成标准。我认为这就是妙佑医疗国际研究方法的一个独特之处,而这种以患者为中心的方式,也是妙佑医疗在众多医疗机构中脱颖而出的原因之一。 部分申请预约概述测试与程序主治医生专业团队临床试验研究患者故事费用与保险Mayo Clinic 新闻转诊 ORG-20420337 医学科室与中心 皮肤科